Dr. Reddy's Laboratories Limited — PPTs, 21-01-2026: Investor Presentation

Dr. Reddy's Q3 FY26 update shows revenue at ₹8,727 Cr, up 4.4% YoY, with EBITDA rising 11% YoY to ₹2,049 Cr. Profit attributable to shareholders was ₹1,210 Cr, down 14% YoY. The company reported a healthy net cash surplus of ₹3,069 Cr.

Business performance saw double-digit growth in its base business (excluding Lenalidomide), with strong contributions from India (+19% YoY), Europe (+20% YoY), and Emerging Markets (+32% YoY) driven by new launches and favorable forex. North America revenues were moderated by lower Lenalidomide sales and pricing pressure.

Strategic focus includes expanding its biosimilar pipeline, with abatacept filed for US and denosumab launched in Germany. New product launches like Hevaxin vaccine and Semaglutide injection in India are key. The integration of the acquired NRT business is 85% complete. The company also signed a strategic collaboration for an immunotherapy oncology drug in Emerging Markets. Management emphasizes strengthening core operations, driving efficiencies, and exploring M&A to augment organic growth.